#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal atresia Hepatitis D Arteriovenous malformation Cardiac failure acute Glomerulonephritis Retinoblastoma ABO haemolytic disease of newborn Mucopolysaccharidosis III Autoimmune myositis Cortical dysplasia Myeloproliferative neoplasm Neuroendocrine tumour of the lung Rett syndrome Allogenic stem cell transplantation Lymphangiosarcoma More trials…

    Learn about Rare Diseases

    Uterine leiomyosarcoma – Trials in Disease Familial amyotrophic lateral sclerosis – Trials in Disease Glycogen storage disease type II – Life with Disease Loeys-Dietz syndrome Factor VIII deficiency – Diagnostics Idiopathic pulmonary fibrosis Pemphigoid – Treatment Leukoencephalopathy – Trials in Disease Mast cell activation syndrome – Trials in Disease Mantle cell lymphoma stage IV More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Efavirenz Trometamol Viltolarsen HUMAN COAGULATION FACTOR XIII Mps-214 Corticosteroids, Plain [14C] DC-806 Trimetazidine Dihydrochloride Sufentanil Citrate Transcon Il-2Β/Γ Gallium (68Ga) Gozetotide Tafasitamab Ds-3939A Permethrin Human Serum Albumin Macrogol 3350 Tenofovir Disoproxil Nifedipine Telisotuzumab Vedotin Terlipressin More therapies…

    Learn about Your Condition

    Thermal burn Shock Retinitis pigmentosa Undifferentiated sarcoma Lumbosacral radiculopathy Soft tissue sarcoma Retroperitoneal cancer Naevoid melanoma Hypoalbuminaemia Proteus syndrome Acute lymphocytic leukaemia Lymphocytic lymphoma Pulmonary resection Viral infection Tardive dyskinesia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder transitional cell carcinoma

  • Study Comparing Gemcitabine and Mitomycin for Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Gemcitabine
    • Mitomycin
    Sweden

  • Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell cancer of the renal pelvis and ureter
    • Transitional cell carcinoma
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    • Infliximab
    Greece Spain

  • Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Atezolizumab
    Belgium Czechia France Germany Greece Ireland +3

  • Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium Czechia France Germany Italy The Netherlands +3

  • Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium France Germany Italy The Netherlands Spain

  • Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Gemcitabine
    • Mitomycin
    France Germany Poland
Previous Page
1 2 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!